drug discovery

See the following -

3 Emerging Open Source Data Analytics Tools Beyond Apache Spark

On the data analytics front, profound change is in the air, and open source tools are leading many of the changes. Sure, you are probably familiar with some of the open source stars in this space, such as Hadoop and Apache Spark, but there is now a strong need for new tools that can holistically round out the data analytics ecosystem. Notably, many of these tools are customized to process streaming data...Streaming data analytics are needed for improved drug discovery...While Apache Spark grabs many of the headlines in the data analytics space, given billions of development dollars thrown at it by IBM and other companies, several unsung open source projects are also on the rise. Here are three emerging data analytics tools worth exploring:

3Rs For Innovating Novel Antibiotics: Sharing Resources, Risks, And Rewards

Anthony D So, Quentin Ruiz-Esparza, Neha Gupta, Otto Cars | BMJ | April 3, 2012

The stream of new antibiotics is struggling to keep up with emerging bacterial resistance. Anthony So and colleagues examine what can be done to increase innovation... Read More »

Award Winners Of CSIR-OSDD-VP Short Film Competition-2013

Anshu Bhardwaj | Open Source Drug Discovery | January 18, 2013

The final screening of the 23 shortlisted videos of CSIR-OSDD-VP Short Film Competition-2013 on “Need of New Drugs for TB” was successfully conducted by a national jury headed by veteran actor / director Shri Amol Palekar in Kolkata during 06-07 January 2013. Read More »

Big Pharma Opens New Chapter On Big Data Collaboration

Dan Munro | Forbes.com | April 8, 2014

In the course of one short week, no less than 3 different models have emerged for sharing big data in the pharmaceutical industry.  The highest profile of these ‒ called Project Data Sphere (PDS here) ‒ was announced earlier today with the official opening of an online resource to share clinical trial data for use in cancer research.

Read More »

Bio-IT World Announces the Winners of Its Tenth Annual Best Practices Awards

Press Release | Bio-IT World, Cambridge Healthtech Institute (CHI) | April 30, 2014

Bio-IT World announced the winners of its tenth annual Best Practices Awards competition this morning in a plenary session at the 2014 Bio-IT World Conference & Expo in Boston. Grand prize winners were named in five life sciences categories highlighting best practices in clinical trial IT, research infrastructure, bioinformatics, cloud computing and data management from AstraZeneca and Tessella, U-BIOPRED, the Pistoia Alliance, Baylor College of Medicine, and Genentech. Read More »

Can Open Innovation Speed Up Drug Development?

Paul A. | IdeaConnection | July 26, 2012

Transparency Life Sciences claims to be the world’s first drug development company based on open innovation. Officially launched in January 2012 it provides a platform for patients, doctors, researchers and various other stakeholders to contribute to the design of clinical studies. Read More »

Cloudera Demos Open Source Precision Medicine and Healthcare Enterprise Data Hub at HIMSS16

Press Release | Cloudera | February 25, 2016

As the Healthcare Information and Management Systems Society (HIMSS) 2016 theme implies -- “transforming health through IT” -- healthcare organizations are increasingly focused on taking advantage of big data to personalize the patient experience and improve clinical outcomes. Cloudera’s commitment to this effort was exemplified this morning, when the company annunced its contributions to President Obama’s Precision Medicine Initiative (PMI). By implementing Cloudera Enterprise, healthcare organizations are better equipped to deliver precision medicine with a modern data platform that facilitates information sharing across silos while remaining HIPAA-compliant...

Read More »

CSIR’s Open Source Drug Discovery is Scouting for CROs to Pursue Advanced Study on TB

Nandita Vijay | Pharmabiz.com | May 5, 2012

The Council of Scientific and Industrial Research (CSIR)'s 'Open Source Drug Discovery' (OSDD) programme is now expanding its drug experimental capabilities. In this regard it is scouting for contract research organizations (CROs) across the country to pursue studies on tuberculosis. Read More »

Culture as a Culprit of the Pharma R&D Crisis

Bruce Booth | Forbes | April 19, 2012

Fundamentally, I think the bulk of the last decade's productivity decline is attributable to a culture problem. The Big Pharma culture has been homogenized, purified, sterilized, whipped, stirred, filtered, etc and lost its ability to ferment the good stuff required to innovate. This isn't covered in most reviews of the productivity challenge facing our industry, because its nearly impossible to quantify, but it's well known and a huge issue.

Read More »

David Ho Highlights Launch of Bio-IT Asia Conference

Kevin Davies and Allison Proffitt | Bio-IT World | June 6, 2012

Ten years after the launch of the Bio-IT World Conference & Expo series in Boston, the conference made its debut in Asia in the sparkling Marina Bay Sands convention center. The trio of speakers who opened the three-day meeting was veteran HIV researcher David Ho, bio-IT consultant Chris Dagdigian, and AstraZeneca bioinformatician Yaron Turpaz.

Read More »

Direct Submissions Of Data To ChEMBL And The Open PHACTS Project

Stefan Senger | ChEMBL-og | May 8, 2013

Don’t we just love the fact that these days so much bioactivity data is freely available at no cost (to the end user)? I think we do. The more, the better. So, what would your answer be if someone asked you if you consider it to be a good idea if they would deposit some of their unpublished bioactivity data in ChEMBL? Read More »

For UNC Scientists, Open Source is the Way Forward

Fibrodysplasia ossificans progressiva—more commonly called stone man's syndrome—is the result of a rare mutation, an anomaly in the way certain enzymes called kinases spur protein synthesis. Someone with stone man's syndrome has hyperactive kinases that catalyze more bone production than they should. The body's natural repair mechanisms malfunction, and they replace soft tissue with deposits of solid bone. Joints freeze. The body becomes a prison. But scientists know they can manipulate those kinases to combat the disease. And chemical biologists at the University of North Carolina are leading an open source effort to unlock the secrets of kinase activity—secrets they say could pioneer a new generation of drug discovery...

Funding Crunch Hits Neglected Diseases Plan

Staff Writer | SciDev.Net | April 29, 2014

The Open Source Drug Discovery (OSDD) programme — a global collaborative initiative supported by the Indian government to find affordable treatment for neglected tropical diseases — has suffered a temporary setback due to a funds crunch caused by tardy submission of funding estimates. Read More »

Global E-Clinical Trial Technologies Market to Reach US$1.37 Billion by 2018, According to New Report by Global Industry Analysts, Inc.

Press Release | Global Industry Analysts, Inc. | July 23, 2012

GIA announces the release of a comprehensive global report on the E-Clinical Trial Technologies markets. The global market for E-Clinical Trial Technologies is forecast to reach US$1.37 billion by the year 2018... Read More »

Griffith Scientists Unlock the “Malaria Box”

Press Release | Griffith University | August 1, 2016

A “Malaria Box” that could hold the answer to discovering new drugs to treat tropical diseases and cancer has been created for researchers around the world. Griffith University tropical disease researchers have joined together with a host of international laboratories to advance drug discovery for major topical diseases through the creation and testing of the Malaria Box. In a paper published this week in the top journal PLoS Pathogens, the global team present findings on a panel of 400 chemical compounds – dubbed the “Malaria Box” – with potential application as therapeutic starting points for diseases like malaria, trypanosomiasis and toxoplasmosis.